“…The intrinsic inhibitory effect of mesenchymal stem cells (MSCs) on tumour growth has been demonstrated with respect to various tumour cell lines such as breast cancer (Clarke et al, 2015), glioblastoma (Dasari et al, 2010;Ho et al, 2013;Yang et al, 2014), liver cancer (Qiao, Xu, Zhao, Ye, & Zhang, 2008), pancreatic cancer (Kidd et al, 2010), prostate cancer, colon cancer (Ohlsson et al, 2003), myeloma (Ciavarella et al, 2012), sarcoma (Khakoo et al, 2006), and lymphoma (Secchiero et al, 2010). Some of the anti-tumour effects contributed by MSCs have been attributed to the secreted factors released by them (Madrigal, demonstrated anti-tumour activity against various solid tumour types (Ahn et al, 2015;Cho et al, 2009;Cortes-Dericks et al, 2016;Ryu et al, 2014;Widowati et al, 2015). We examined the effect of secreted components present in the ADSC-conditioned medium (ADSC-CM) and their effect in combination with the Wnt antagonist secreted frizzled-related protein-4 (sFRP4) may generate enhanced anti-tumour activity in breast cancer cells.…”